Home
NTLA
NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on June 2, 2025

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

21 hours ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

21 hours ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

21 hours ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

21 hours ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

21 hours ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

21 hours ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Man Utd sign Brazil forward Cunha from Wolves

AFP

21 hours ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

21 hours ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Zacks

3 days ago

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia stock dips following safety event in Phase III gene therapy trial

Clinical Trials Arena

3 days ago

Intellia stock dips following safety event in Phase III gene therapy trial

Morningstar Research

3 days ago

Analyst Report: Intellia Therapeutics, Inc.

MT Newswires

4 days ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday

MT Newswires

4 days ago

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

Investing.com

4 days ago

Intellia stock tumbles on safety concerns

MT Newswires

4 days ago

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating

Intellia filing spurs safety concerns over CRISPR drug

BioPharma Dive

4 days ago

Intellia filing spurs safety concerns over CRISPR drug

MT Newswires

14 days ago

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

MT Newswires

14 days ago

Top Premarket Gainers

MT Newswires

14 days ago

Intellia Therapeutics Says Drug Shows Potential in Phase 1 Transthyretin Amyloidosis Trial

GlobeNewswire

15 days ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Zacks

18 days ago

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

Simply Wall St.

22 days ago

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Simply Wall St.

23 days ago

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

Zacks

24 days ago

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

MT Newswires

24 days ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating

MT Newswires

24 days ago

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com

24 days ago

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Morningstar Research

25 days ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

25 days ago

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

GlobeNewswire

25 days ago

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Zacks

a month ago

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a month ago

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks

a month ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Zacks

a month ago

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

GlobeNewswire

a month ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

a month ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Zacks

a month ago

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Trump’s FDA Sends a Bullish Signal to Biotech

The Wall Street Journal

a month ago

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Investor's Business Daily

a month ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

MT Newswires

a month ago

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires

a month ago

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Insider Monkey

2 months ago

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Clinical Trials Arena

2 months ago

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Pharmaceutical Technology

2 months ago

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

2 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

MT Newswires

2 months ago

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey

2 months ago

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

2 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks

2 months ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

Zacks

2 months ago

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

MT Newswires

2 months ago

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire

2 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

The Fly

3 months ago

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

MT Newswires

3 months ago

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

3 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks

3 months ago

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

MT Newswires

3 months ago

RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk

MT Newswires

3 months ago

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

Morningstar Research

3 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com

3 months ago

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Intellia Therapeutics Inc Earnings Call

MT Newswires

3 months ago

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

3 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

3 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks

3 months ago

What's in Store for These 5 Biotech Stocks This Earnings Season?

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Motley Fool

3 months ago

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Zacks

3 months ago

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

GlobeNewswire

3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Insider Monkey

4 months ago

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Zacks

4 months ago

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey

4 months ago

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

4 months ago

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires

4 months ago

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires

4 months ago

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

Clinical Trials Arena

4 months ago

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks

4 months ago

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

MT Newswires

4 months ago

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire

4 months ago

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia makes progress on HAE study; 2 more China drug deals

BioPharma Dive

4 months ago

Intellia makes progress on HAE study; 2 more China drug deals

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks

5 months ago

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Zacks

5 months ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Zacks

5 months ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Pharmaceutical Technology

5 months ago

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

TipRanks

5 months ago

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

TipRanks

5 months ago

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

Benzinga

5 months ago

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Zacks

5 months ago

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Intellia to stop work on rare disease therapy, lay off staff

BioPharma Dive

5 months ago

Intellia to stop work on rare disease therapy, lay off staff

MT Newswires

5 months ago

Intellia Therapeutics to Workforce by 27%, Halt Some Programs

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

GlobeNewswire

5 months ago

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

MT Newswires

5 months ago

BofA Securities Adjusts Price Target on Intellia Therapeutics to $50 From $58, Maintains Buy Rating

Share on Social Networks: